Disease on EC 1.3.99.5 - 3-oxo-5alpha-steroid 4-dehydrogenase (acceptor)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
3(or 17)beta-hydroxysteroid dehydrogenase deficiency
Masculinizing genitoplasty in intersex patients.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
5?-Reductase-2 deficiency: is gender assignment recommended in infancy? Two case-reports and review of the literature.
5alpha-reductase activity in the prostate.
5alpha-reductase activity of genital and nongenital skin fibroblasts from patients with 5alpha-reductase deficiency, androgen insensitivity, or unknown forms of male pseudohermaphroditism.
5alpha-reductase type 2 mutations are present in some boys with isolated hypospadias.
A new mutation of 5-alpha-reductase type 2 (A62E) in a large Egyptian kindred.
A novel frameshift mutation in the 5alpha-reductase type 2 gene in Korean sisters with male pseudohermaphroditism.
A novel homozygous disruptive mutation in the SRD5A2-gene in a partially virilized patient with 5alpha-reductase deficiency.
A novel mutation of 5alpha-steroid reductase 2 deficiency (CD 65 ALA-PRO) with severe virilization defect in a Turkish family and difficulty in gender assignment.
A study of gender outcome of Egyptian patients with 46,XY disorder of sex development.
Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5alpha-reductase deficiency.
Binding of androgens in 5 alpha-reductase-deficient human genital skin fibroblasts: inhibition by progesterone and its metabolites.
Choice of gender in 5alpha-reductase deficiency: a moving target.
Clinical characterization and analysis of the SRD5A2 gene in six Korean patients with 5alpha-reductase type 2 deficiency.
Clinical, biochemical and morphologic diagnostic markers in an infant male pseudohermaphrodite patient with compound heterozygous mutations (G115D/R246W) in SRD5A2 gene.
Definitive diagnosis of enzymatic deficiencies of steroidogenesis in at-risk newborns and infants by urinary marker analysis using GC/MS-SIM.
Diagnosis of 5alpha-reductase deficiency in a teenage Turkish girl.
Diagnosis of 5alpha-reductase type 2 deficiency: contribution of anti-Müllerian hormone evaluation.
Difficulties in Diagnosis and Treatment of 5alpha-Reductase Type 2 Deficiency in a Newborn with 46,XY DSD.
Disorders linked to insufficient androgen action in male children.
Early diagnosis of 5alpha-reductase deficiency in newborns.
Endocrinology of male infertility: evaluation and treatment.
Etiological studies of severe or familial hypospadias.
Evaluation of the tubular and interstitial functions of the testis in 46,XY patients with ambiguous genitalia.
Evidence that steroid 5alpha-reductase isozyme genes are differentially methylated in human lymphocytes.
Five novel mutations of SRD5A2 found in eight Chinese patients with 46,XY disorders of sex development.
Gender identity of children and young adults with 5alpha-reductase deficiency.
Genetic analysis of the SRD5A2 gene in Indian patients with 5alpha-reductase deficiency.
Genotype-phenotype correlation, gonadal malignancy risk, gender preference, and testosterone/dihydrotestosterone ratio in steroid 5-alpha-reductase type 2 deficiency: a multicenter study from Turkey.
Homozygous Ala65Pro Mutation with V89L Polymorphism in SRD5A2 Deficiency.
Homozygous mutation (A228T) in the 5alpha-reductase type 2 gene in a boy with 5alpha-reductase deficiency: genotype-phenotype correlations.
Hypospadias.
Identification of mutations in the SRD5A2 gene in Thai patients with male pseudohermaphroditism.
Induction of a deficiency of steroid delta 4-5 alpha-reductase activity in liver by a porphyrinogenic drug.
Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Intranuclear binding of [3H]dihydrotestosterone by cultured human fibroblasts.
Long-term surgical results and patient satisfaction with male pseudohermaphroditism or true hermaphroditism: a cohort of 63 patients.
Masculinizing genitoplasty in intersex patients.
Minimal External Masculinization in a SRY-negative XX Male Podenco Dog.
Molecular analysis of 5alpha-reductase type 2 gene in eight unrelated egyptian children with suspected 5alpha-reductase deficiency: prevalence of the G34R mutation.
Molecular analysis of the AR and SRD5A2 genes in patients with 46,XY disorders of sex development.
Molecular characterization of 6 unrelated Italian patients with 5alpha-reductase type 2 deficiency.
New frameshift mutation in the 5alpha-reductase type 2 gene in a Brazilian patient with 5alpha-reductase deficiency.
New mutations, hotspots, and founder effects in Brazilian patients with steroid 5alpha-reductase deficiency type 2.
Phenotypic variability in 17beta-hydroxysteroid dehydrogenase-3 deficiency and diagnostic pitfalls.
Phenotypic variation in a family with partial androgen insensitivity syndrome explained by differences in 5alpha dihydrotestosterone availability.
Pituitary-gonadal axis in male undermasculinisation.
Practical approach to steroid 5alpha-reductase type 2 deficiency.
Prolonged human chorionic gonadotrophin stimulation as a tool for investigating and managing undescended testes.
RECOGNITION OF 5-ALPHA REDUCTASE-2 DEFICIENCY IN AN ADULT FEMALE 46XY DSD CLINIC.
Screening for mutations for 17 ?-hydroxysteroid dehydrogenase and androgen receptor in an adult female 46, XY DSD clinic.
Sigmoid colon vaginoplasty in children.
Squamous cell carcinoma of the vagina in a male pseudohermaphrodite with 5alpha-reductase deficiency.
Stable maintenance of 5alpha-reductase activity in long-term subcultures of fibroblasts derived from the foreskin.
Steroid 5alpha-reductase deficiency in man. An inherited form of male pseudohermaphroditism.
Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism.
Steroidogenesis of the testis -- new genes and pathways.
The hair follicle: a paradoxical androgen target organ.
The role of the pediatrician in the management of children with genital ambiguities.
Undervirilization in XY newborns may hide a 5alpha-reductase deficiency: report of three new SRD5A2 gene mutations.
Uniparental disomy in steroid 5alpha-reductase 2 deficiency.
[5alpha-reductase type 2 deficiency: experiences from Campinas (SP) and Salvador (BA)]
[Steroid 5alpha-reductase deficiency]
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Characterising SRD5A2 Gene Variants in 37 Indonesian Patients with 5-Alpha-Reductase Type 2 Deficiency.
Molecular characterization of 6 unrelated Italian patients with 5alpha-reductase type 2 deficiency.
3beta-hydroxysteroid 3-dehydrogenase deficiency
Evaluation of the tubular and interstitial functions of the testis in 46,XY patients with ambiguous genitalia.
Masculinizing genitoplasty in intersex patients.
Abortion, Spontaneous
Fetal alpha 5-reductase Val89Leu mutation is associated with late miscarriage.
Acne Vulgaris
19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
5alpha-reductase: history and clinical importance.
Acne: effect of hormones on pathogenesis and management.
Androgen metabolism in sebaceous glands from subjects with and without acne.
Immunolocalization of 5alpha-reductase isozymes in acne lesions and normal skin.
Inhibition of 5alpha-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro.
Longer TA repeat but not V89L polymorphisms in the SRD5A2 gene may confer acne risk in the Chinese population.
MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
MK386: a potent, selective inhibitor of the human type 1 5alpha-reductase.
The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne.
Adenocarcinoma
Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor.
Adrenal Hyperplasia, Congenital
Definitive diagnosis of enzymatic deficiencies of steroidogenesis in at-risk newborns and infants by urinary marker analysis using GC/MS-SIM.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Adrenoleukodystrophy
New findings on X-linked Adrenoleukodystrophy: 5alpha-reductase isoform 2 relative gene expression is modified in affected fibroblasts.
Alopecia
19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
5alpha-Reductase Isozymes in the Prostate.
5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
5alpha-reductase: history and clinical importance.
A new look at the 5alpha-reductase inhibitor finasteride.
Acne: effect of hormones on pathogenesis and management.
Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia.
Biochemical roles of testosterone and epitestosterone to 5 alpha-reductase as indicators of male-pattern baldness.
Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily.
Changes of metabolic profile in men treated for androgenetic alopecia with 1 mg finasteride.
Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men.
Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.
Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia.
Current management of androgenetic alopecia in men.
Delayed telogen replacement in a boy's scalp.
Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia.
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite.
Effect of Cuscuta reflexa Roxb on androgen-induced alopecia.
Effect of testosterone metabolites on ABC half-transporter relative gene expression in X-linked adrenoleukodystrophy.
Establishment of type II 5alpha-reductase over-expressing cell line as an inhibitor screening model.
Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration.
Expression of androgen receptor coactivator ARA70/ELE1 in androgenic alopecia.
Finasteride in the treatment of alopecia.
Finasteride in the treatment of men with frontal male pattern hair loss.
Finasteride treatment and neuroactive steroid formation.
Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women.
Finasteride, a Type 2 5alpha-reductase inhibitor, in the treatment of men with androgenetic alopecia.
Finasteride: a review of its use in male pattern hair loss.
Genetic analysis of male pattern baldness and the 5alpha-reductase genes.
Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG).
Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.
Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?
Relationship of Early-Onset Baldness to Prostate Cancer in African-American Men.
Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics.
Selected variants of the steroid-5-alpha-reductase isoforms SRD5A1 and SRD5A2 and the sex steroid hormone receptors ESR1, ESR2 and PGR: no association with female pattern hair loss identified.
Spermatozoa and chronic treatment with finasteride: a TEM and FISH study.
Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasteride.
The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
The extract of Thujae occidentalis semen inhibited 5alpha-reductase and androchronogenetic alopecia of B6CBAF1/j hybrid mouse.
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles.
Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition.
Ultrasound-activated particles as CRISPR/Cas9 delivery system for androgenic alopecia therapy.
Urinary steroid measurements in some endocrine and psychiatric diseases.
Urinary steroids in women with androgenic alopecia.
Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss).
Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old.
Androgen-Insensitivity Syndrome
Clinical and Laboratorial Features That May Differentiate 46,XY DSD due to Partial Androgen Insensitivity and 5?-Reductase Type 2 Deficiency.
Clinical, biochemical and morphologic diagnostic markers in an infant male pseudohermaphrodite patient with compound heterozygous mutations (G115D/R246W) in SRD5A2 gene.
Disorders linked to insufficient androgen action in male children.
Etiological studies of severe or familial hypospadias.
Evaluation of the tubular and interstitial functions of the testis in 46,XY patients with ambiguous genitalia.
Investigation of androgen receptor gene mutations in a series of 21 patients with 46,XY disorders of sex development.
Masculinizing genitoplasty in intersex patients.
Molecular analysis of the AR and SRD5A2 genes in patients with 46,XY disorders of sex development.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Screening for mutations in candidate genes for hypospadias.
Stable maintenance of 5alpha-reductase activity in long-term subcultures of fibroblasts derived from the foreskin.
Steroid metabolism in the gonads of a patient with testicular feminization. II. Metabolism of c19- and c18-steroids in vitro.
The role of the pediatrician in the management of children with genital ambiguities.
Transcription of androgen receptor and 5alpha-reductase II in genital fibroblasts from patients with androgen insensitivity syndrome.
aromatase deficiency
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Azoospermia
5Alpha-reductase type 2 genes in Japanese males do not appear to be associated with cryptorchidism.
Mutation screening for the 5alpha-reductase type 2 gene in Japanese men with idiopathic azoospermia.
Steroid 5alpha-reductase 2 gene melting polymorphisms in male subjects with azoospermia or oligospermia.
Breast Neoplasms
5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production.
5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
A49T, V89L and TA repeat polymorphisms of steroid 5alpha-reductase type II and breast cancer risk in Japanese women.
Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells.
Androgens in human breast carcinoma.
Associations between the SRD5A2 gene V89L and TA repeat polymorphisms and breast cancer risk: a meta-analysis.
Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment.
Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.
Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer Risk.
Intracrinology of estrogens and androgens in breast carcinoma.
Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma.
Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.
SRD5A2 gene polymorphisms affect the risk of breast cancer.
TA repeat polymorphism of the 5alpha-reductase gene and breast cancer.
The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics.
The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer.
Carcinogenesis
Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143.
Involvement of Egr-1 in HGF-induced elevation of the human 5alpha-R1 gene in human hepatocellular carcinoma cells.
Mammary steroid metabolizing enzymes in relation to hyperplasia and tumorigenesis in the dog.
Polymorphisms in androgen metabolism genes AR, CYP1B1, CYP19, and SRD5A2and prostate cancer risk and aggressiveness in Bulgarian patients.
Promoting effects of antiandrogenic agents on rat ventral prostate carcinogenesis induced by 3,2'-dimethyl-4-aminobiphenyl (DMAB).
Carcinoma
A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro.
Alterations of peripheral testosterone matabolism after induced hypoprolactinemia in patients with prostatic carcinoma.
Anti-androgenic activity of fatty acids.
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate.
Combined treatment of Dunning R3327 rat prostatic tumor with the 5alpha-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide.
Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats.
Effect of the dual 5alpha-reductase inhibitor PNU 157706 on the growth of dunning R3327 prostatic carcinoma in the rat.
Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Effects of various pesticides on human 5alpha-reductase activity in prostate and LNCaP cells.
Expression of 5alpha-reductases in human epithelial ovarian cancer: its correlation with androgen receptor status.
Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders.
In situ androgen producing enzymes in human prostate cancer.
Promoting effects of antiandrogenic agents on rat ventral prostate carcinogenesis induced by 3,2'-dimethyl-4-aminobiphenyl (DMAB).
Squamous cell carcinoma of the vagina in a male pseudohermaphrodite with 5alpha-reductase deficiency.
Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5alpha-reductase and steroid aromatase.
[The effect of hormonal agents on the development of chronic laryngitis and tumor disease. Report of two cases]
Carcinoma, Ductal
5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
Carcinoma, Hepatocellular
Feminization of hepatic S metabolism in male rats with a transplanted (MtT/F4).
Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search.
Involvement of Egr-1 in HGF-induced elevation of the human 5alpha-R1 gene in human hepatocellular carcinoma cells.
The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
Carcinoma, Ovarian Epithelial
Expression of 5alpha-reductases in human epithelial ovarian cancer: its correlation with androgen receptor status.
Carcinoma, Squamous Cell
Squamous cell carcinoma of the vagina in a male pseudohermaphrodite with 5alpha-reductase deficiency.
[The effect of hormonal agents on the development of chronic laryngitis and tumor disease. Report of two cases]
Cryptorchidism
5Alpha-reductase type 2 genes in Japanese males do not appear to be associated with cryptorchidism.
Differences in testicular development between 5alpha-reductase 2 deficiency and isolated bilateral cryptorchidism.
Polymorphisms of MAMLD1, SRD5A2, and AR Candidate Genes in Seven Dogs (78,XY; SRY-Positive) Affected by Hypospadias or Cryptorchidism.
Prolonged human chorionic gonadotrophin stimulation as a tool for investigating and managing undescended testes.
Cysts
Allopregnanolone, pregnenolone sulfate, and epitestosterone in breast cyst fluid.
Denys-Drash Syndrome
Pituitary-gonadal axis in male undermasculinisation.
Diabetes Mellitus, Type 2
Androgenic correlates of genetic variation in the gene encoding 5alpha-reductase type 1.
Disorder of Sex Development, 46,XY
5alpha-reductase activity of genital and nongenital skin fibroblasts from patients with 5alpha-reductase deficiency, androgen insensitivity, or unknown forms of male pseudohermaphroditism.
A novel frameshift mutation in the 5alpha-reductase type 2 gene in Korean sisters with male pseudohermaphroditism.
A novel missense mutation of 5-alpha reductase type 2 gene (SRD5A2) leads to severe male pseudohermaphroditism in a Turkish family.
Diminished 5alpha-reductase activity in extracts of fibroblasts cultured from patients with familial incomplete male pseudohermaphroditism, type 2.
Gender identity of children and young adults with 5alpha-reductase deficiency.
Genetic linkage mapping of the human steroid 5 alpha-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23-->p22.
Identification of mutations in the SRD5A2 gene in Thai patients with male pseudohermaphroditism.
Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Diagnosis, psychological evaluation, and management.
Masculinizing genitoplasty in intersex patients.
New frameshift mutation in the 5alpha-reductase type 2 gene in a Brazilian patient with 5alpha-reductase deficiency.
Normal bone density in male pseudohermaphroditism due to 5alpha- reductase 2 deficiency.
Role of dihydrotestosterone in androgen action.
Steroid 5alpha-reductase deficiency in man. An inherited form of male pseudohermaphroditism.
Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism.
Steroid 5alpha-reductase in cultured human fibroblasts. Biochemical and genetic evidence for two distinct enzyme activities.
Uniparental disomy in steroid 5alpha-reductase 2 deficiency.
Disorders of Sex Development
A novel mutation of the 5alpha-reductase type 2 gene in two unrelated Egyptian children with ambiguous genitalia.
A novel SRD5A2 mutation in a Taiwanese newborn with ambiguous genitalia.
A novel SRD5A2 mutation in an Iranian family with sex development disorder.
Clinical and Laboratorial Features That May Differentiate 46,XY DSD due to Partial Androgen Insensitivity and 5?-Reductase Type 2 Deficiency.
Correlation of androgen receptor and SRD5A2 gene mutations with pediatric hypospadias in 46, XY DSD children.
Exome sequencing identified compound heterozygous mutations in the SRD5A2 gene in a case of 46,XY ambiguous genitalia.
Five novel mutations of SRD5A2 found in eight Chinese patients with 46,XY disorders of sex development.
Genome analyses and androgen quantification for an infant with 5?-reductase type 2 deficiency.
Long-term surgical outcome of masculinizing genitoplasty in large cohort of patients with disorders of sex development.
Molecular analysis of the AR and SRD5A2 genes in patients with 46,XY disorders of sex development.
Molecular diagnosis of 5alpha-reductase-2 gene mutation in two Indian families with male pseudohermaphroditism.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Mutational Analysis of Androgen Receptor (AR) Gene in 46,XY Patients with Ambiguous Genitalia and Normal Testosterone Secretion: Endocrinological Characteristics of Three Patients with AR Gene Mutations.
Novel compound heterozygous mutations in the SRD5A2 gene from 46,XY infants with ambiguous external genitalia.
Novel mutations of the SRD5A2 and AR genes in Thai patients with 46, XY disorders of sex development.
Phenotype, Sex of Rearing, Gender Re-Assignment, and Response to Medical Treatment in Extended Family Members with a Novel Mutation in the SRD5A2 Gene.
Practical approach to steroid 5alpha-reductase type 2 deficiency.
RECOGNITION OF 5-ALPHA REDUCTASE-2 DEFICIENCY IN AN ADULT FEMALE 46XY DSD CLINIC.
Sexual differentiation.
Spectrum of Pathogenic Variants in SRD5A2 in Indian Children with 46,XY Disorders of Sex Development and Clinically Suspected Steroid 5?-Reductase 2 Deficiency.
Steroid 5alpha-reductase deficiency in man. An inherited form of male pseudohermaphroditism.
The role of the pediatrician in the management of children with genital ambiguities.
Dwarfism
Brassinosteroid deficiency due to truncated steroid 5alpha-reductase causes dwarfism in the lk mutant of pea.
Dyskinesias
5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction.
Endocrine System Diseases
19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
Endometrial Hyperplasia
Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders.
Endometrial Neoplasms
Altered expression of lysophosphatidic acid receptors, in association with the synthesis of estrogens and androgens in type 1 endometrial cancer biology.
Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders.
Important roles of the AKR1C2 and SRD5A1 enzymes in progesterone metabolism in endometrial cancer model cell lines.
Endometriosis
Androgen receptor and 5alpha-reductase are expressed in pelvic endometriosis.
Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line.
Epilepsy
Characterization of the 5alpha-reductase-3alpha-hydroxysteroid dehydrogenase complex in the human brain.
Expression of 5alpha-reductase and 3alpha-hydroxisteroid oxidoreductase in the hippocampus of patients with chronic temporal lobe epilepsy.
Epilepsy, Absence
Finasteride inhibits the progesterone-induced spike-wave discharges in a genetic model of absence epilepsy.
Epilepsy, Temporal Lobe
Expression of 5alpha-reductase and 3alpha-hydroxisteroid oxidoreductase in the hippocampus of patients with chronic temporal lobe epilepsy.
Erectile Dysfunction
Comorbid LUTS and erectile dysfunction: optimizing their management.
Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
Impact of medical treatments for benign prostatic hyperplasia on sexual function.
Medical management of benign prostatic hypertrophy.
Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting.
The role of combination medical therapy in benign prostatic hyperplasia.
Fetal Death
Fetal death in mice lacking 5alpha-reductase type 1 caused by estrogen excess.
Fibroadenoma
Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma.
Genetic Diseases, Inborn
Aetiology of hypospadias: a systematic review of genes and environment.
Gingival Overgrowth
Phenytoin-mediated androgen metabolism in gingival fibroblasts. Effects of the antiandrogen finasteride and the alkaline phosphatase inhibitor levamisole.
The effects of human mast-cell products and of phenytoin on androgen 5alpha-reductase expression in human gingival fibroblasts.
Glioma
Adrenergic activation of steroid 5alpha-reductase gene expression in rat C6 glioma cells: involvement of cyclic amp/protein kinase A-mediated signaling pathway.
Dihydrotestosterone Induces Proliferation, Migration, and Invasion of Human Glioblastoma Cell Lines.
Influence of 17beta-estradiol on the synthesis of reduced neurosteroids in the brain (in vivo) and in glioma cells (in vitro): possible relevance to mental disorders in women.
Influence of serum-free culture conditions on steroid 5alpha-reductase mRNA expression in rat C6 glioma cells.
Influence of serum-free culture conditions on subcellular localization of steroid 5alpha-reductase in rat C6 glioma cells.
Nerve growth factor induces elevation of steroid 5alpha-reductase mRNA levels in rat C6 glioma cells through expression of transcription factor Egr-1.
Serotonergic 5-HT2A receptor stimulation induces steroid 5alpha-reductase gene expression in rat C6 glioma cells via transcription factor Egr-1.
Trichostatin A Stimulates Steroid 5alpha-Reductase Gene Expression in Rat C6 Glioma Cells via a Mechanism Involving Sp1 and Sp3 Transcription Factors.
Glucose Intolerance
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.
Gonadal Dysgenesis
A study of gender outcome of Egyptian patients with 46,XY disorder of sex development.
Evaluation of the tubular and interstitial functions of the testis in 46,XY patients with ambiguous genitalia.
Gene dosage imbalances in patients with 46,XY gonadal DSD detected by an in-house-designed synthetic probe set for multiplex ligation-dependent probe amplification analysis.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
The role of the pediatrician in the management of children with genital ambiguities.
Gonadal Dysgenesis, Mixed
Masculinizing genitoplasty in intersex patients.
Gynecomastia
The identification of 5 alpha-reductase-2 and 17 beta-hydroxysteroid dehydrogenase-3 gene defects in male pseudohermaphrodites from a Turkish kindred.
Hematuria
Post-coital gross hematuria: an unusual presentation of benign prostatic hyperplasia.
Hepatitis
Sex hormone influence on hepatitis in young male A/JCr mice infected with Helicobacter hepaticus.
Hepatitis C
Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.
Hepatitis C, Chronic
Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.
Hirsutism
19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism.
The evaluation and management of hirsutism.
Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women.
Hypercholesterolemia
Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin.
Hyperprolactinemia
Alterations of peripheral testosterone matabolism after induced hypoprolactinemia in patients with prostatic carcinoma.
Effects of metoclopramide on mRNA levels of 5alpha-reductase isozymes in rat brain.
Effects of sulpiride on mRNA levels of steroid 5alpha-reductase isozymes in prostate of adult rats.
Effects of sulpiride on prolactin and mRNA levels of steroid 5alpha-reductase isozymes in adult rat brain.
Hyperthyroidism
Comprehensive study of urinary cortisol metabolites in hyperthyroid and hypothyroid patients.
Hypertrichosis
Clinical assessment and serum hormonal profile in prepubertal hypertrichosis.
Hypogonadism
Effect of testosterone metabolites on ABC half-transporter relative gene expression in X-linked adrenoleukodystrophy.
Endocrinology of male infertility: evaluation and treatment.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5alpha-reductase and steroid aromatase.
Hypospadias
5alpha-reductase type 2 mutations are present in some boys with isolated hypospadias.
A Novel SRD5A2 Mutation with Loss of Function Identified in Chinese Patients with Hypospadias.
A49T, R227Q and TA repeat polymorphism of steroid 5 alpha-reductase type II gene and Hypospadias risk in North Indian children.
Aetiology of hypospadias: a systematic review of genes and environment.
Association between SRD5A2 polymorphism and hypospadias: a meta-analysis.
Association of SRD5A2 gene mutations with risk of hypospadias in the Iranian population.
Characterization With Gene Mutations in Han Chinese Patients With Hypospadias and Function Analysis of a Novel AR Genevariant.
Correlation of androgen receptor and SRD5A2 gene mutations with pediatric hypospadias in 46, XY DSD children.
Cri-du-chat (5p-) syndrome presenting with cerebellar hypoplasia and hypospadias: Prenatal diagnosis and aCGH characterization using uncultured amniocytes.
Expression of Xenobiotic Biomarkers CYP1 Family in Preputial Tissue of Patients with Hypospadias and Phimosis and Its Association with DNA Methylation Level of SRD5A2 Minimal Promoter.
Family History is Underestimated in Children with Isolated Hypospadias: A French Multicenter Report of 88 Families.
Genetic Polymorphisms of 17beta-Hydroxysteroid Dehydrogenase 3 and the Risk of Hypospadias.
Genetics of hypospadias: are single-nucleotide polymorphisms in SRD5A2, ESR1, ESR2, and ATF3 really associated with the malformation?
Genotype-phenotype correlation and identification of two novel SRD5A2 mutations in 33 Chinese patients with hypospadias.
Hypospadias in a Male (78,XY; SRY-Positive) Dog and Sex Reversal Female (78,XX; SRY-Negative) Dogs: Clinical, Histological and Genetic Studies.
Hypospadias risk and polymorphism in SRD5A2 and CYP17 genes: case-control study among Indian children.
Metabolism of androstenedione in skin and serum levels of gonadotrophins and androgens in prepubertal boys with hypospadias.
Molecular diagnosis of 46,XY DSD and identification of a novel 8 nucleotide deletion in exon 1 of the SRD5A2 gene.
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Mutation analysis of five candidate genes in Chinese patients with hypospadias.
Mutation analysis of the SRD5A2, AR and SF-1 genes in 52 Chinese boys with hypospadias.
Polymorphisms of MAMLD1, SRD5A2, and AR Candidate Genes in Seven Dogs (78,XY; SRY-Positive) Affected by Hypospadias or Cryptorchidism.
Prenatal exposure to di-n-butyl phthalate (DBP) differentially alters androgen cascade in undeformed versus hypospadiac male rat offspring.
Screening for mutations in candidate genes for hypospadias.
Steroid 5-alpha-reductase type 2 (SRD5A2) gene V89L polymorphism and hypospadias risk: A meta-analysis.
Steroid 5alpha-reductase 1 polymorphisms and testosterone/dihydrotestosterone ratio in male patients with hypospadias.
The Effect of Intramuscular Testosterone Enanthate Treatment on Stretched Penile Length in Prepubertal Boys With Hypospadias.
The valine allele of the V89L polymorphism in the 5-alpha-reductase gene confers a reduced risk for hypospadias.
Urethral development in the fetal rabbit and induction of hypospadias: a model for human development.
[Identification of mutations of SRD5A2 gene and SRY gene in patients with hypospadias]
[Karyotyping and analysis of 5? -reductase-2 gene mutation in 25 patients with hypospadias].
[Mutation analysis of SRD5A2 gene in patients with hypospadias]
Infertility
Differences in testicular development between 5alpha-reductase 2 deficiency and isolated bilateral cryptorchidism.
Infertility, Male
5-Alfa reductase type 2 (SRD5A2) gene rs523349 polymorphism is not associated with non-obstructive azoospermia in Turkish patients.
Insulin Resistance
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.
Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss.
Klinefelter Syndrome
Masculinizing genitoplasty in intersex patients.
Laryngitis
[The effect of hormonal agents on the development of chronic laryngitis and tumor disease. Report of two cases]
Leydig Cell Tumor
Expression of aromatase cytochrome P450 in rat H540 Leydig tumor cells.
Liver Diseases
Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.
Liver Neoplasms
Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.
Lordosis
Inhibiting biosynthesis and/or metabolism of progestins in the ventral tegmental area attenuates lordosis of rats in behavioural oestrus.
Lymphatic Metastasis
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
Melanoma
Sebocytes are the key regulators of androgen homeostasis in human skin.
Metabolic Syndrome
Single-nucleotide polymorphism in the 5-?-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
Myoclonus
Estrogen increases latencies to seizures and levels of 5alpha-pregnan-3alpha-ol-20-one in hippocampus of wild-type, but not 5alpha-reductase knockout, mice.
Neoplasm Metastasis
5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
[Expression of SRD5A1 and its prognostic role in prostate cancer: Analysis based on the data-mining of ONCOMINE].
Neoplasms
'Urology: Today's Advances, Tomorrow's Clinical Practice', Cannes, November 2003. Current thinking in prostatic diseases: insights into dual 5alpha-reductase inhibitor therapy in BPH and prostate cancer.
5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice.
Adrenal microsomal C19-steroid 5alpha-reductase activity in the Snell transplantable rat adrenocortical tumour 494 and the effect of oestradiol, testosterone propionate and adrenocorticotrophin in intact and gonadectomized rats.
Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men.
Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
Association of SRD5A2 genotype and pathological characteristics of prostate tumors.
Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men.
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.
Changes in hepatic steroid metabolism in rat following transplantation of four different clones of pituitary tumor cells.
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis.
Combined treatment of Dunning R3327 rat prostatic tumor with the 5alpha-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide.
Conserved effect of aging on DNA methylation and association with EZH2 polycomb protein in mice and humans.
Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue.
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency.
DNA Methyl Transferase 1 Reduces Expression of SRD5A2 in the Aging Adult Prostate.
DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats.
Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Expression of 5alpha-reductases in human epithelial ovarian cancer: its correlation with androgen receptor status.
Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.
Expression of aromatase cytochrome P450 in rat H540 Leydig tumor cells.
Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.
Expression of the insulin-like growth factor (IGF) system and steroidogenic enzymes in canine testis tumors.
Feminization of hepatic S metabolism in male rats with a transplanted (MtT/F4).
Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.
Gene expression of androgen metabolising enzymes in benign prostatic hyperplasia.
Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif.
Genotype-phenotype correlation, gonadal malignancy risk, gender preference, and testosterone/dihydrotestosterone ratio in steroid 5-alpha-reductase type 2 deficiency: a multicenter study from Turkey.
Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling.
In situ androgen production in human gastric carcinoma--androgen synthesizing and metabolizing enzymes.
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer.
Involvement of Egr-1 in HGF-induced elevation of the human 5alpha-R1 gene in human hepatocellular carcinoma cells.
Joint effects of inflammation and androgen metabolism on prostate cancer severity.
Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
Localization and altered expression of AKR1C family members in human ovarian tissues.
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Mammary steroid metabolizing enzymes in relation to hyperplasia and tumorigenesis in the dog.
Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
Prevention of prostate-related cancers in Lobund-Wistar rats.
Prevention, complementary therapies, and new scientific developments in the field of prostate cancer.
Progesterone metabolism in normal human endometrium during the menstrual cycle and in endometrial carcinoma.
Promoting effects of antiandrogenic agents on rat ventral prostate carcinogenesis induced by 3,2'-dimethyl-4-aminobiphenyl (DMAB).
Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.
RE: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Rising prostate-specific antigen after primary treatment of prostate cancer: sequential hormone manipulation.
Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.
Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression.
Some new approaches to potential test systems for drugs against prostatic cancer.
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Understanding the epidemiology, natural history, and key pathways involved in prostate cancer.
Words of wisdom. Re: Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. Kramer BS, Hagerty KL, Justman S, et al.
[Expression of type I and type II 5alpha-reductase isoenzymes in prostate cancer tissues]
Neuroinflammatory Diseases
Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition.
Obesity
Activation of the hypothalamic-pituitary-adrenal axis in obesity: cause or consequence?
Obesity, Abdominal
Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver.
Oligospermia
Steroid 5alpha-reductase 2 gene melting polymorphisms in male subjects with azoospermia or oligospermia.
Ovarian Neoplasms
Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.
Consortium analysis of 7 candidate SNPs for ovarian cancer.
Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes.
The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
Ovotesticular Disorders of Sex Development
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Paget Disease, Extramammary
Androgen receptor and 5alpha-reductase immunohistochemical profiles in extramammary Paget disease.
Parkinson Disease
Comparative non-radioactive RT-PCR assay: an approach to study the neurosteroids biosynthetic pathway in humans.
Peripheral Arterial Disease
ICAM-1 and SRD5A1 gene polymorphisms in symptomatic peripheral artery disease.
Phimosis
Expression of Xenobiotic Biomarkers CYP1 Family in Preputial Tissue of Patients with Hypospadias and Phimosis and Its Association with DNA Methylation Level of SRD5A2 Minimal Promoter.
Stable maintenance of 5alpha-reductase activity in long-term subcultures of fibroblasts derived from the foreskin.
Placental Insufficiency
Changes in 5alpha-pregnane steroids and neurosteroidogenic enzyme expression in fetal sheep with umbilicoplacental embolization.
Polycystic Ovary Syndrome
5alpha-reductase activity in women with polycystic ovary syndrome.
Association of genetic variants in the two isoforms of 5?-reductase, SRD5A1 and SRD5A2, in lean patients with polycystic ovary syndrome.
In silico and functional studies reveal novel loss-of-function variants of SRD5A2, but no variants explaining excess 5?-reductase activity.
Increased 5alpha-reductase and normal 11beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome.
The 5alpha-reductase type 1, but not type 2, gene is expressed in anagen hairs plucked from the vertex area of the scalp of hirsute women and normal individuals.
Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women.
Porphyria, Acute Intermittent
Induction of a deficiency of steroid delta 4-5 alpha-reductase activity in liver by a porphyrinogenic drug.
Porphyrias
Induction of a deficiency of steroid delta 4-5 alpha-reductase activity in liver by a porphyrinogenic drug.
Prostatic Diseases
'Urology: Today's Advances, Tomorrow's Clinical Practice', Cannes, November 2003. Current thinking in prostatic diseases: insights into dual 5alpha-reductase inhibitor therapy in BPH and prostate cancer.
5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
DNA Methyl Transferase 1 Reduces Expression of SRD5A2 in the Aging Adult Prostate.
Lessons learned about prostatic transformation from the age-related methylation of 5?-reductase type 2 gene.
The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Prostatic Hyperplasia
19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH.
A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period.
A new look at the 5alpha-reductase inhibitor finasteride.
A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
alpha(1)-Blocker therapy in the nineties: focus on the disease.
An update on the use of 5alpha-reductase inhibitors.
Androgen-independent basal cell re-epithelialization, c-erbB-2 mRNA expression and androgen-dependent EGFr mRNA expression in benign prostatic hyperplasia explant cultures treated with finasteride.
Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence?
Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men.
Benign prostatic hyperplasia progression and its impact on treatment.
Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II.
Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride.
Cactus flower extracts may prove beneficial in benign prostatic hyperplasia due to inhibition of 5alpha reductase activity, aromatase activity and lipid peroxidation.
Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study.
Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride.
Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate.
Clinical Usefulness of Serum Prostate Specific Antigen for the Detection of Prostate Cancer is Preserved in Men Receiving the Dual 5alpha-Reductase Inhibitor Dutasteride.
Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
Comorbid LUTS and erectile dysfunction: optimizing their management.
Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency.
DNA Methyl Transferase 1 Reduces Expression of SRD5A2 in the Aging Adult Prostate.
Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite.
Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells.
Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia.
Dynamic contrast enhanced magnetic resonance imaging as a biological marker to noninvasively assess the effect of finasteride on prostatic suburethral microcirculation.
Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study.
Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia.
Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy.
Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men.
Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility.
Extracts of Phyllostachys pubescens Leaves Represses Human Steroid 5-Alpha Reductase Type 2 Promoter Activity in BHP-1 Cells and Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia in Rat Model.
Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.
Future concepts in the medical therapy of benign prostatic hyperplasia.
Genetic polymorphism in sex hormone metabolism and prostate cancer risk.
Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
In vitro modulation of steroid 5alpha-reductase activity by phospholipases in epithelium and stroma of human benign prostatic hyperplasia.
Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex.
Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Is there a place for combination medical therapy?
Isolation and pharmacological characterization of fatty acids from saw palmetto extract.
Joint effects of inflammation and androgen metabolism on prostate cancer severity.
Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.
Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia.
Longer (TA)n Repeat but not A49T and V89L Polymorphisms in SRD5A2 Gene May Confer Prostate Cancer Risk in South Indian Men.
Managing benign prostatic hyperplasia.
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Methyl esters of N-(dicyclohexyl)acetyl-piperidine-4-(benzylidene-4-carboxylic acids) as drugs and prodrugs: a new strategy for dual inhibition of 5 alpha-reductase type 1 and type 2.
Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
New innovative therapies for benign prostatic hyperplasia: any advance?
Pharmacotherapy for nocturia in the elderly patient.
Phospholipase A2 degradation products modulate epithelial and stromal 5alpha-reductase activity of human benign prostatic hyperplasia in vitro.
Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPH.
Prevention of benign prostatic hyperplasia disease.
Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study.
Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5 .
Protective effect of Prostane in experimental prostatic hyperplasia in rats.
Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3.
Refractory overactive bladder in men: update on novel therapies.
Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.
Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics.
Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
Self organizing molecular field analysis on a series of human 5alpha-reductase inhibitors: Unsaturated 3-carboxysteroid.
Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer.
Spermatozoa and chronic treatment with finasteride: a TEM and FISH study.
SRD5A1 and SRD5A2 are Associated with the Treatment for Benign Prostatic Hyperplasia with the Combination of 5?-reductase Inhibitors and ?-adrenergic-receptor Antagonist.
SRD5A2 Gene Polymorphisms and the Risk of Benign Prostatic Hyperplasia but not Prostate Cancer.
Stable expression of human 5alpha-reductase type II in COS1 cells due to chromosomal gene integration: a novel tool for inhibitor identification.
Steroid 5alpha-reductase inhibitors.
Structure-activity relationship for inhibition of 5alpha-reductase by triterpenoids isolated from Ganoderma lucidum.
Testosterone 5?-reductase inhibition by free fatty acids from Sabal serrulata fruits.
The effect of 5alpha-reductase inhibition with finasteride and dutasteride on bone mineral density in older men with benign prostatic hyperplasia.
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
The mechanism of epristeride against benign prostatic hyperplasia.
The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis.
The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
The role of combination medical therapy in benign prostatic hyperplasia.
Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR.
Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease.
Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS.
Z-350, a novel compound with alpha 1-adrenoceptor antagonistic and steroid 5 alpha-reductase inhibitory actions: pharmacological properties in vivo.
[Drug therapy for benign prostatic hyperplasia. Systematic overview]
[Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?]
[Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers]
[Expression and significance of steroid 5alpha-reductase isoenzymes in benign hyperplastic prostate tissues]
[Medical combination therapy in LUTS suggestive of BPH.]
[Modern pharmacotherapy of benign prostatic hyperplasia]
Prostatic Intraepithelial Neoplasia
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Understanding the epidemiology, natural history, and key pathways involved in prostate cancer.
Prostatic Neoplasms
'Urology: Today's Advances, Tomorrow's Clinical Practice', Cannes, November 2003. Current thinking in prostatic diseases: insights into dual 5alpha-reductase inhibitor therapy in BPH and prostate cancer.
19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
5alpha-reductase isozymes and androgen actions in the prostate.
5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3.
5alpha-Reductase Isozymes in the Prostate.
5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro.
A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.
A review of phase III clinical trials of prostate cancer chemoprevention.
Agents in development for prostate cancer prevention.
Allelic frequencies of six polymorphic markers for risk of prostate cancer.
Androgen antagonists: Potential role in prostate cancer prevention.
Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men.
Androgen metabolism genes in prostate cancer health disparities.
Anti-androgenic activity of fatty acids.
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.
Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.
Association of Polymorphisms in the VDR, CYP17 and SRD5A2 Genes and Prostate Cancer Among Lebanese Men
Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II.
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.
Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride.
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
Chemoprevention of prostate cancer with finasteride.
Chemoprevention of prostate cancer.
Chemoprevention of prostate cancer: agents and study designs.
Chemoprevention using dutasteride: the REDUCE trial.
Chemopreventive trials in urologic cancer.
Chemotherapeutic prevention studies of prostate cancer.
Clinical Usefulness of Serum Prostate Specific Antigen for the Detection of Prostate Cancer is Preserved in Men Receiving the Dual 5alpha-Reductase Inhibitor Dutasteride.
Combinatorial androgen receptor targeted therapy for prostate cancer.
Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis.
Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Current drug therapy for prostate cancer: an overview.
CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population.
Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma.
Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
Determination of sulfates of androsterone and epiandrosterone in human serum using isotope diluted liquid chromatography-electrospray ionization-mass spectrometry.
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer.
Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency.
Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells.
Dutasteride prior to contrast-enhanced colour Doppler ultrasound prostate biopsy increases prostate cancer detection.
Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats.
Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Effect of the dual 5alpha-reductase inhibitor PNU 157706 on the growth of dunning R3327 prostatic carcinoma in the rat.
Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells.
Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer.
Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients.
Factors controlling the expression of 5alpha-reductase in human prostate: A possible new approach for the treatment of prostate cancer.
Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line.
Finasteride.
Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor.
GEN GEN: the genomic genetic analysis of androgen-metabolic genes and prostate cancer as a paradigm for the dissection of complex phenotypes.
Genetic polymorphism in sex hormone metabolism and prostate cancer risk.
Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk.
Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
Heterogeneity in genetic susceptibility to prostate cancer.
Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease.
High-grade prostate cancer and finasteride.
Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue.
Importance of 5?-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
In silico and functional studies reveal novel loss-of-function variants of SRD5A2, but no variants explaining excess 5?-reductase activity.
In situ androgen producing enzymes in human prostate cancer.
Inherited variation in hormone-regulating genes and prostate cancer survival.
Inhibition of 5alpha-reductase in the rat prostate by Cimicifuga racemosa.
Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143.
Inverse regulation of DHT synthesis enzymes 5? Reductase Types 1 and 2 by the androgen receptor in prostate cancer.
Joint effects of inflammation and androgen metabolism on prostate cancer severity.
Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
Lifestyle determinants of 5alpha-reductase metabolites in older African-American, white, and Asian-American men.
Longer (TA)n Repeat but not A49T and V89L Polymorphisms in SRD5A2 Gene May Confer Prostate Cancer Risk in South Indian Men.
Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.
New frontiers in androgen biosynthesis and metabolism.
New progesterone derivatives as inhibitors of 5alpha-reductase enzyme and prostate cancer cell growth.
No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
Pancreaticoduodenal arterial rupture and hemoabdomen in ACI/SegHsd rats with polyarteritis nodosa.
Perspective: prostate cancer susceptibility genes.
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy.
Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
Polymorphisms in androgen metabolism genes AR, CYP1B1, CYP19, and SRD5A2and prostate cancer risk and aggressiveness in Bulgarian patients.
Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians.
Polymorphisms of HPC2/ELAC2 and SRD5A2 (5?-Reductase Type II) Genes in Prostate Cancer.
Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor.
Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue.
Prevalent mutations in prostate cancer.
Preventing diseases of the prostate in the elderly using hormones and nutriceuticals.
Prevention of prostate-related cancers in Lobund-Wistar rats.
Prostate cancer chemoprevention: Current status and future prospects.
Prostate cancer prevention.
Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Prostate cancer: a serious disease suitable for prevention.
Provocative aspects of androgen genetics.
Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.
RE: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Re: The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
Redistribution of androgen receptors in acquired hormone-refractory prostate cancer cells.
Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial.
Regulation of aromatase and 5alpha-reductase by 25-hydroxyvitamin D(3), 1alpha,25-dihydroxyvitamin D(3), dexamethasone and progesterone in prostate cancer cells.
Relationship between SRD5A2 rs9282858 polymorphism and the susceptibility of prostate cancer: A meta-analysis based on 20 publications.
Relationship of Early-Onset Baldness to Prostate Cancer in African-American Men.
Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor.
Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population.
Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.
Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH.
Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer.
Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression.
Some new approaches to potential test systems for drugs against prostatic cancer.
SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
SRD5A2 gene expression inhibits cell migration and invasion in prostate cancer cell line via F-actin reorganization.
SRD5A2 Gene Polymorphisms and the Risk of Benign Prostatic Hyperplasia but not Prostate Cancer.
SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.
SRD5A2 V89L polymorphism and prostate cancer risk: A meta-analysis.
Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer.
Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis.
Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.
Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.
Structure of human steroid 5?-reductase 2 with the anti-androgen drug finasteride.
Systematic meta-analyses of gene-specific genetic association studies in prostate cancer.
Tests for genetic association using family data.
The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.
The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels.
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study.
The influence of finasteride on the development of prostate cancer.
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
The Motion: All Men Over the Age of 50 Should be Encouraged to Take a 5alpha-Reductase Inhibitor to Prevent Prostate Cancer.
The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer.
Theaflavin-3,3'-digallate and penta-O-galloyl-beta-D-glucose inhibit rat liver microsomal 5alpha-reductase activity and the expression of androgen receptor in LNCaP prostate cancer cells.
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.
V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression.
Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5alpha-reductase and steroid aromatase.
Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.
VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.
Words of wisdom. Re: Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. Kramer BS, Hagerty KL, Justman S, et al.
[Association between A49T polymorphism of SRD5A2 gene and risk of prostate cancer]
[Chemoprevention of prostate cancer. Current status]
[Chemoprevention of prostate cancer]
[Drug therapy for benign prostatic hyperplasia. Systematic overview]
[Expression of SRD5A1 and its prognostic role in prostate cancer: Analysis based on the data-mining of ONCOMINE].
[Expression of type I and type II 5alpha-reductase isoenzymes in prostate cancer tissues]
[Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer]
[Influence of dihydrotestosterone deficit on treatment of prostatic diseases regarding to contemporary methods of prostatic hypertrophy treatments]
[Role of 5alpha-reductase inhibitors in the chemoprevention of prostate cancer].
[V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer].
Prostatitis
Experimental autoimmune prostatitis: dihydrotestosterone influence over the immune response.
The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis.
Seizures
Allopregnanolone, the active metabolite of progesterone protects against neuronal damage in picrotoxin-induced seizure model in mice.
Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy.
Estrogen increases latencies to seizures and levels of 5alpha-pregnan-3alpha-ol-20-one in hippocampus of wild-type, but not 5alpha-reductase knockout, mice.
Finasteride, a 5alpha-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice.
Long-term social isolation enhances picrotoxin seizure susceptibility in mice: up-regulatory role of endogenous brain allopregnanolone in GABAergic systems.
Progesterone reduces pentylenetetrazol-induced ictal activity of wild-type mice but not those deficient in type I 5alpha-reductase.
Seizure activity is increased in endocrine states characterized by decline in endogenous levels of the neurosteroid 3 alpha,5 alpha-THP.
Social isolation stress and neuroactive steroids.
[Androgens and epilepsy].
Seminoma
Expression of the insulin-like growth factor (IGF) system and steroidogenic enzymes in canine testis tumors.
Sleep Deprivation
Changes in the expression of steroid metabolism-related genes in rat adrenal glands during selective REM sleep deprivation.
Influence of sleep disturbance on steroid 5alpha-reductase mRNA levels in rat brain.
steroid 11beta-monooxygenase deficiency
Molecular genetics of disorders of sex development in a highly consanguineous population.
Testicular Neoplasms
Single-nucleotide polymorphism in the 5-?-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
Urinary Bladder Neck Obstruction
Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate.
Z-350, a novel compound with alpha 1-adrenoceptor antagonistic and steroid 5 alpha-reductase inhibitory actions: pharmacological properties in vivo.
[Clinical and urodynamic evaluation of efficacy of conservative treatment of urination disorders in patients with benign prostate hyperplasia].
Urinary Retention
Benign prostatic hyperplasia progression and its impact on treatment.
Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate.
Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting.
The role of dihydrotestosterone in benign prostatic hyperplasia.
Update on the use of dutasteride in the management of benign prostatic hypertrophy.
Urinary retention and post-void residual urine in men: separating truth from tradition.
[Pharmacological treatment of benign prostatic hyperplasia.]
Uterine Cervical Neoplasms
Altered urinary profiles of polyamines and endogenous steroids in patients with benign cervical disease and cervical cancer.
Varicose Veins
Elevated sex steroid hormones in great saphenous veins in men.
Wilms Tumor
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
New frontiers on the molecular underpinnings of hypospadias according to severity.